Holen Sie sich die Stockscreener-App
13.52
0.22%
0.03
Handel nachbörslich:
13.53
0.010
+0.07%
Schlusskurs vom Vortag:
$13.49
Offen:
$13.49
24-Stunden-Volumen:
3.02M
Relative Volume:
0.37
Marktkapitalisierung:
$3.55B
Einnahmen:
$6.16B
Nettoeinkommen (Verlust:
$246.00M
KGV:
14.40
EPS:
0.9387
Netto-Cashflow:
$708.00M
1W Leistung:
-0.22%
1M Leistung:
+1.05%
6M Leistung:
+67.95%
1J Leistung:
+34.93%
1-Tages-Spanne:
$13.48
$13.53
1-Wochen-Bereich:
$13.46
$13.58
52-Wochen-Spanne:
$5.69
$13.60
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.52 | 3.55B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Sun Pharma to Acquire Organon in US$11.75 Billion Deal, Strengthening Global Healthcare Portfolio - eHealth Magazine
Organon (OGN) Q1 2026 earnings summary - Quartr
Price-Driven Insight from (OGN) for Rule-Based Strategy - Stock Traders Daily
Organon (OGN) Proxy filing Summary - Quartr
SBI Joins 10 Global Lenders in Sun Pharma's Organon Financing Deal - outlookbusiness.com
SBI joins global banks to fund Sun's Organon buy - Magzter
What Sparked Organon's Recent Stock Surge - Kavout | AI
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada - AOL.com
SBI joins global banks to fund Sun Pharma's $11.75 billion Organon buy - Business Standard
Organon to present VTAMA cream data at pediatric dermatology meeting - Investing.com
Organon to present VTAMA cream data at pediatric dermatology meeting By Investing.com - Investing.com Nigeria
Organon’s VTAMA data heads to pediatric dermatology meeting - Stock Titan
Sun Pharma's $11.8 bn Organon buy drives India's M&A value to 4-year high - Business Standard
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
OGNOrganon & Co Volatility & Greeks - Finviz
OGN Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesShare Repurchase Impact - dars.gov.et
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets? - Insider Monkey
Organon & Co. Actuals & Estimates (NYSE:OGN) - TradingView
Organon & Co updates strategic focus, shares watched on NYSE - AD HOC NEWS
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Class Action Lawsuit Filed: Organon & Co. (OGN)Join by July 22, 2025Contact Levi & Korsinsky - The National Law Review
Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP - TradingView
Price to earnings forward of Organon & Co. – NYSE:OGN - TradingView
Price to earnings forward of Organon & Co. – LSE:0A9W - TradingView
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada - MSN
Mayne Pharma appoints former Organon & Co executive Meghan Rivera to board - MSN
(OGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of Organon & Co. – NYSE:OGN - TradingView
Enterprise value to EBITDA forward of Organon & Co. – LSE:0A9W - TradingView
Enterprise value to revenue forward of Organon & Co. – NYSE:OGN - TradingView
Shareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Organon & Co. (OGN) InvestorsLead Plaintiff Deadline on July 22, 2025 - The National Law Review
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
FINAL OGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Org - The National Law Review
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Organon & Co. (OGN) - The National Law Review
Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Securities Fraud Class Action Filed Against Organon & Co. (OGN) - The National Law Review
Enterprise value to EBIT forward of Organon & Co. – LSE:0A9W - TradingView
Organon & Co updates earnings timing, shares watched by health care investors - Ad-hoc-news.de
Organon celebrates 5 years of expanding healthcare access - Manila Standard
Organon & Co (OGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organon & Co stock hits 52-week high at $13.49 - Investing.com UK
Organon & Co stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? - TradingView
OGN Forecast — Price Target — Prediction for 2027 - TradingView
Gorvins supports Organon Trustees through acquisition process - Marketing Stockport
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):